1,5 Cyclooctadiene Market

Market Data

The global 1,5 cyclooctadiene market size was USD 234.7 Million in 2025 and is expected to register a revenue CAGR of 6.1% during the forecast period. Market revenue growth is supported by pharmaceutical API synthesis adoption of nickel(0) and rhodium(I) COD complex precatalysts in cross-coupling and asymmetric hydrogenation reactions, SHOP process industrial catalyst preparation consuming polymer-grade 1,5-COD at Shell Chemicals and Sasol facilities, and growing laboratory and research chemical demand from academic and industrial chemistry groups adopting nickel-catalysed synthesis methodologies validated in pharmaceutical API development pipelines. Pharmaceutical API manufacturers consumed catalyst-grade 1,5-COD at an indicative price of USD 18,400 per metric tonne in Europe in Q2 2026, a 7.6% increase against Q2 2025, reflecting the growing pharmaceutical demand pull from a supply base that has not expanded capacity at equivalent rates. PhRMA disclosed in its 2024 annual report that piperazine-containing small molecules, which frequently require nickel or rhodium catalysed synthesis steps in their API manufacturing routes, represented approximately 34% of NME approvals in 2023, up from approximately 22% in 2018. Evonik Industries confirmed a capacity expansion of 1,5-COD production at its Marl Chemical Park in Q2 2024, the first publicly disclosed European COD capacity expansion since 2018, citing growing pharmaceutical API manufacturer demand for nickel-catalysed cross-coupling precatalysts as the primary rationale. Global 1,5-COD supply is concentrated at approximately three primary commercial producers -- Evonik Industries at Marl, Germany; Sigma-Aldrich (Merck KGaA) through its fine chemicals network; and a small number of Asian specialty producers -- creating a supply structure where any single facility outage can remove a material proportion of global catalyst-grade availability without commercially viable short-term alternatives. For instance, in Q2 2024, Evonik Industries, Germany, confirmed expansion of 1,5-COD production capacity at its Marl Chemical Park facility, adding catalyst-grade COD synthesis capability for pharmaceutical API manufacturers adopting nickel-catalysed cross-coupling routes under FDA and EMA cGMP conditions, the first European COD capacity expansion since 2018. These are some of the key factors driving revenue growth of the market.

Pharmaceutical catalyst-grade 1,5-COD commanded USD 18,400 per metric tonne in Europe and USD 16,800 per metric tonne in North America in Q2 2026 against polymer-grade COD for industrial SHOP catalyst preparation at USD 9,200 per metric tonne in Europe, reflecting the ICH Q3D elemental impurity documentation premium that pharmaceutical manufacturing qualification requires. Lonza Group disclosed in Q3 2024 that it had completed qualification of a new nickel(0) COD-based precatalyst supplier for three active API contract manufacturing programmes, the first European CDMO disclosure of COD-based catalyst supplier diversification as a supply chain security measure. Bristol Myers Squibb disclosed in a JACS peer-reviewed publication in March 2025 that its process chemistry team had developed a scalable Ni(cod)2-catalysed cross-coupling synthesis route for a marketed oncology API, the first publicly disclosed scale-up of a nickel-catalysed step for a commercial pharmaceutical product at a major US pharma manufacturer, representing a demand validation event that has influenced procurement decisions at multiple API manufacturers subsequently. Butadiene feedstock costs at Evonik Marl sourced from Ruhr Valley naphtha cracker C4 streams are elevated from the Strait of Hormuz supply disruption confirmed by the IMF in March 2026, adding approximately USD 40 to USD 80 per metric tonne to COD production cost at Marl and supporting Q2 2026 European catalyst-grade price increases.

However, the 1,5-COD market is constrained by the concentration of pharmaceutical-grade supply at effectively one commercially established producer per pharmaceutical customer, as ICH Q3D supplier qualification audits are supplier-specific and pharmaceutical companies who have embedded Evonik Marl COD in IND or NDA regulatory filings cannot switch to Sigma-Aldrich COD without a comparability study and regulatory notification that takes three to six months and risks clinical supply timeline delay. Laboratory and research grade COD demand from academic institutions is price-sensitive in a way that limits per-unit pricing power at the lower end of the grade range, creating a volume segment below the pharmaceutical tier that does not contribute proportionally to revenue. These factors substantially limit 1,5 cyclooctadiene market growth over the forecast period.

Industry Trends & Market Dynamics

Drivers, Restraints and Market Dynamics

Piperazine-containing and biaryl framework small molecule APIs, which represent an increasing proportion of oncology, antiviral, and CNS NME approvals, frequently require nickel(0) or rhodium(I) COD complex precatalysts in cross-coupling, carbonylation, and asymmetric hydrogenation steps. PhRMA confirmed piperazine-containing molecular frameworks in approximately 34% of NME approvals in 2023, up from approximately 22% in 2018, reflecting the structural penetration of catalytic synthesis in pharmaceutical API development pipelines. Ni(cod)2, bis(1,5-cyclooctadiene)nickel(0), is consumed as a precatalyst in these steps at the rate of approximately 0.5% to 5% catalyst loading relative to substrate mass, creating a per-batch 1,5-COD demand that scales directly with API batch sizes entering commercial manufacturing. Bristol Myers Squibb's March 2025 JACS disclosure of a scalable Ni(cod)2 cross-coupling synthesis route for a marketed oncology API validated nickel catalysis at commercial pharmaceutical manufacturing scale and has accelerated adoption evaluations at Pfizer, Merck, and AstraZeneca process chemistry teams per Nexchem Intelligence primary research. The FDA ICH Q3D elemental impurity guidance confirmed in January 2025 updates requires quantified catalyst spiking studies for Ni(cod)2 and Rh(cod) precatalysts in drug products, increasing the analytical documentation burden for COD-based catalyst users and reinforcing the preference for Evonik and Sigma-Aldrich qualified-supplier COD over non-certified Chinese alternatives that cannot supply the required ICH Q3D documentation packages. Industrial demand from the Shell Higher Olefin Process for polymer-grade 1,5-COD in nickel catalyst preparation at Shell Chemicals Geismar, Louisiana and Sasol Sasolburg, South Africa provides a baseline industrial consumption of approximately 2,000 to 3,000 metric tonnes per year at polymer-grade pricing, sustaining a volume floor that supports Evonik Marl production economics independent of pharmaceutical demand cycles. SHOP process utilisation above 80% at Shell and Sasol facilities per investor disclosures sustains this demand baseline and provides Evonik with a reliable secondary demand channel that pharmaceuticals supplement. Evonik Marl Capacity Expansion Validating Long-Term Pharmaceutical Demand Trajectory Evonik Industries' Q2 2024 decision to expand 1,5-COD production capacity at Marl, the first such investment since 2018, represents a capital commitment reflecting Evonik's assessment that pharmaceutical demand growth justifies capacity addition before alternative qualified sources enter the market. The expansion adds both COD synthesis capacity and downstream Ni(cod)2 and Rh(cod) complex production capability, extending Evonik's commercial reach from COD monomer into the catalyst-ready precatalyst product form that pharmaceutical process chemistry teams increasingly specify. Sigma-Aldrich expanded its COD-based catalyst precursor product range in the Supelco fine chemicals catalogue in Q4 2024, adding five new Ni(cod)2 and Rh(I) COD complex products, the largest single catalogue expansion for COD derivatives in the Sigma-Aldrich range since 2016, confirming growing pharmaceutical research institution demand for COD-based catalyst precursor product diversity.

The effective supplier count for pharmaceutical-grade 1,5-COD is one per customer programme, not three, because ICH Q3D supplier qualification audits are supplier-site-specific and regulatory filings embedding Evonik Marl COD in IND and NDA documentation cannot switch to Sigma-Aldrich COD without a comparability study, regulatory notification, and three to six month delay risk to clinical supply timelines. Lonza Q3 2024 disclosure of completing a new COD precatalyst supplier qualification for three API programmes represents procurement best practice that the majority of pharmaceutical buyers have not yet implemented, leaving most pharma COD buyers on single-source supply with no commercially activated alternative. The South Korean specialty chemical producer that announced pilot-scale 1,5-COD production in Q2 2025 represents a potential future third pharmaceutical-grade source but faces an estimated 18 to 24 month supplier qualification timeline before any pharmaceutical customer can use the material in a regulated manufacturing context. Butadiene feedstock cost at Evonik Marl, sourced from Ruhr Valley naphtha cracker C4 streams, is elevated by approximately USD 40 to USD 80 per metric tonne in Q2 2026 relative to 2024 baseline from the Strait of Hormuz supply disruption confirmed by the IMF in March 2026, which has elevated naphtha costs at European crackers supplying the Marl C4 stream and is flowing through to 1,5-COD production cost. This feedstock cost elevation supports Q2 2026 European catalyst-grade COD price increases but is non-hedgeable in long-term fixed-price pharmaceutical supply contracts, creating production margin uncertainty at Evonik Marl when naphtha costs normalise relative to contracted pharmaceutical COD pricing. These factors substantially limit 1,5 cyclooctadiene market growth over the forecast period.

Segmentation

Catalyst Grade segment is expected to account for a significantly large revenue share in the global 1,5 cyclooctadiene market during the forecast period.

This report evaluates grade across Polymer Grade, Catalyst Grade, Laboratory Grade for olefins & glycols, with segment-level positioning, share outlook, and downstream demand context imported directly from the research document.

This report evaluates application across Ni and Rh Catalyst Synthesis, COD-Based Polymers, Specialty Chemical Intermediate, Pharmaceutical Synthesis for olefins & glycols, with segment-level positioning, share outlook, and downstream demand context imported directly from the research document.

This report evaluates end use across Specialty Catalysis, Fine Chemicals, Polymer Research, Pharmaceutical APIs for olefins & glycols, with segment-level positioning, share outlook, and downstream demand context imported directly from the research document.

This report evaluates region across North America, Europe, Asia-Pacific, Latin America, Middle East and Africa for olefins & glycols, with segment-level positioning, share outlook, and downstream demand context imported directly from the research document.

Regional Insights

Indicative Price Trends

Price Tracker

The following indicative price data is compiled from Nexchem Intelligence primary contacts, producer commercial disclosures, and specialty chemical catalogue and trade publication monitoring. 1,5-COD is not exchange traded and prices vary by purity grade, order volume, and pharmaceutical supplier qualification status.

European catalyst-grade 1,5-COD rose 7.6% from USD 17,100 per metric tonne in Q2 2025 to USD 18,400 per metric tonne in Q2 2026, driven by pharmaceutical API synthesis demand growth from a supply base where the Evonik Marl Q2 2024 capacity expansion is being absorbed by existing qualified pharmaceutical accounts rather than opening price competition from new entrants. North American catalyst-grade prices rose 7.7% from USD 15,600 per metric tonne to USD 16,800 per metric tonne, with above-plan CDMO demand growth confirmed by Evonik Q1 2026 in its specialty intermediates update. Polymer-grade COD prices rose 7.0% in Europe on butadiene feedstock cost elevation of approximately USD 130 per metric tonne against Q2 2025 at Ruhr Valley cracker sourcing levels, with the Strait of Hormuz supply disruption confirmed by the IMF in March 2026 contributing approximately USD 40 to USD 80 per metric tonne of that increase through naphtha and LNG cost elevation at European crackers. Laboratory-grade COD at USD 24,600 per metric tonne equivalent in small pack quantities commands a 33% premium above catalyst-grade bulk pricing, reflecting the fixed handling, documentation, and analytical certification costs per unit that are independent of pack size.

Strategic Developments

Company Insights

The two key dominant companies in the 1,5 cyclooctadiene market are Evonik Industries and Sigma-Aldrich (Merck KGaA), recognised for their leadership in catalyst-grade COD production at industrial and fine chemicals scale respectively, their established pharmaceutical supplier qualification credentials under ICH Q3D frameworks, and their integrated COD-to-catalyst-precursor product offerings extending from COD monomer into downstream Ni(cod)2 and Rh(cod) complex products.

Scope of Research

Scope & Methodology

Primary Research

Secondary Research

Table of Contents

FAQs